Developments in the treatment of juvenile arthritis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1485-1496

  Reiff, Andreas Otto ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Juvenile arthritis; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FOLIC ACID; FOLINIC ACID; GAMMA INTERFERON; IBUPROFEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TOLMETIN; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VALDECOXIB;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ASEPTIC MENINGITIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AVASCULAR NECROSIS; CHICKENPOX; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHILL; CLINICAL TRIAL; CUSHING DISEASE; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HEADACHE; HUMAN; HYPOTENSION; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MORBIDITY; MYALGIA; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCYTOPENIA; PHYSICIAN ATTITUDE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SKIN MANIFESTATION; TERATOGENICITY; TUBERCULOSIS; VOMITING; WHOLE BODY RADIATION;

ARTHRITIS, JUVENILE RHEUMATOID; DOUBLE-BLIND METHOD; HUMANS; MULTICENTER STUDIES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 3543107952     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1485     Document Type: Review

References (110)

1. OEN KG: Comparative epidemiology of the rheumatic diseases in children. Curr. Opin. Rheumatol. (2000) 12(5):410-414.
2. GARE BA: Juvenile arthritis- who gets it, where and when? A review of the current data on incidence and prevalence. Clin. Exp. Rheumatol. (1999) 17(3):367-374.
3. MANNERS PJ, BOWER C: Worldwide prevalence of juvenile arthritis why does it vary so much? J. Rheumatol. (2002) 29:1520-1530.
4. LAWRENCE RC, HELMICK CG, ARNETT FC et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. (1998) 41(5):778-799.
5. CASSIDY JT, PETTY RE: Juvenile rheumatoid arthritis. In: Textbook of pediatric rheumatology. WB Saunders, Philadelphia, USA (1995):133-223.
6. JACOBS JC: Juvenile rheumatoid arthritis. In: Pediatric rheumatology for the practitioner. Springer-Verlag, New York, NY, USA (1993):231-359.
7. SIEGEL DM, BAUM J: Juvenile arthritis. Prim. Care (1993) 20:883-893.
8. SULLIVAN DB, CASSIDY JT, PETTY RE: Pathogenic implications of age of onset in juvenile rheumatoid arthritis. Arthritis Rheum. (1975) 18:251-255.
9. CASSIDY JT, LEVINSON JE, BASS JC et al.: A study of classification criteria for a diagnosis of Juvenile rheumatoid arthritis. Arthritis Rheum. (1986) 29:274-281.
10. PETTY RE, SOUTHWOOD TR, BAUM J et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J. Rheumatol. (1998) 25(10):1991-1994.
11. DENARDO BA, MILLER LC, SCHALLER JG et al.: Young children with juvenile rheumatoid arthritis (JA) are developmentally delayed in gross and fine motor skills. Arthritis Rheum. (1996) 39(Suppl. 9):S1715.
12. DAVID J, COOPER C, HICKEY L et al.: The fanctional and psychological outcomes of juvenile chronic arthritis in young adulthood. Br. J. Rheumatol. (1994) 33:876-881.
13. WOO P, WEDDERBURN LR: Juvenile chronic arthritis. Lancet (1998) 351:969-973.
14. FANTINI F, GERLONI V, GATTINARA M et al.: Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10-year follow up [abstract]. Arthritis Rheum. (1999) 42(9 Suppl.):S168.
15. BIANCHI ML, BARDARE M, GALBIATI E et al.: Bone development in juvenile rheumatoid arthritis. In: Paediatric osteology. Prevention of osteoporasis - a paediatric task? Schönau E, Matkovic V, (Eds). Proceedings of the 2nd International Workshop on Paediatric Osteology, Elsevier Science, Cologne, Singapore (1998):173-181.
16. BERNSTEIN B, TAKAHASHI M, HANSON V: Cardiac involvement in juvenile rheumatoid arthritis. J. Pediatr. (1974) 85(3):313-317.
17. WALLACE CA, LEVINSON JE: Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. North Am. (1991) 17(4):891-905.
18. GÄRE BA, FASTH A: The natural history of juvenile chronic arthritis: a population based cohort study, I: Onset and disease process. J. Rheumatol. (1995) 22:295-307.
19. GUILLAUME S, PRIEUR AM, COSTE J et al.: Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. (2000) 43:1858-1865.
20. MINDEN K, KIESSLING U, LISTING J et al.: Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J. Rheumatol. (2000) 27:2256-2263.
21. PETERSON LS, MASON T, NELSON AM et al.: Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum. (1997) 40:2235-2240.
22. ZAK M, PEDERSEN FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford)(2000) 39:198-204.
23. FOSTER HE, MARSHALL N, MYERS A et al.: Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. (2003) 48(3):767-775.
24. PACKHAM JC, HALL MA, PIMM TJ: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (2002) 41(12):1444-1449.
25. PACKHAM JC, HALL MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (2002) 41(12):1440-1443.
26. PACKHAM JC, HALL MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: education and employment. Rheumatology (2002) 41(12):1436-1439.
27. PACKHAM JC, HALL MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (2002) 41(12):1428-1435.
28. EGSMOSE C, LUND B, BORG G et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year follow-up of a prospective double blind placebo controlled study. J. Rheumatol. (1995) 22:2208-2213.
29. VAN DER HEIDE A, JACOBS JWG, BIJLSMA JWJ et al.: The effectiveness of early treatment with 'second-line' antirheumatic drugs: a randomized, controlled trial. Ann. Intern. Med. (1996) 124:699-707.
30. FLATØ B, AASLAND A, VINJE O, FØRRE Ø: Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J. Rheumatol. (1998) 25:366-375.
31. FANTINI F, GERLONI V, GATTINARA M et al.: Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10-year follow up [abstract]. Arthritis Rheum. (1999) 42(9 Suppl.):S168.
32. GIANNINI EH, CASSIDY JT, BREWER EJ et al.: Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin. Arthritis Rheum. (1993) 23:34-46.
33. CLEARY AG, MURPHY HD, DAVIDSON JE: Intra-articular corticosteroid injections in juvenile idiopathic arthritis (review). Arch. Dis. Child. (2003) 88(3):192-196.
34. ATHREYA BH, CASSIDY JT: Current status of the medical treatment of children with juvenile rheumatoid arthritis. Rheum. Dis. Clin. North Am. (1991) 17:871-889.
35. SINGSEN BH, GOLDBACH-MANSKY R: Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum. Dis. Clin. North Am. (1997) 23:811-840.
36. GIANNINI EH, BREWER EJ, KUZMINA N et al.: Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA.-USS.R. double-blind, placebo-controlled trial. N. Engl. J. Med. (1992) 326:1043-1049.
37. HALLE F, PRIEUR AM: Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin. Exp. Rheumatol. (1991) 9:297-302.
38. GOTTLIEB BS, KEENAN GF, LU T, ILOWITE NT: Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics (1997) 100(6):994-997.
39. WALLACE CA, SHERRY DD: Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J. Rheumatal. (1992) 19:1604-1607.
40. REIFF A, SHAHAM B, WOOD BP et al.: High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. (1995) 13:113-118.
41. HAREL L, WAGNER-WEINER L, POZNANSKI AK et al.: Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. (1993) 36:1370-1374.
42. RAVELLI A, GERLONI V, CORONA F et al.: Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin. Exp. Rheumatol. (1998) 16:181-183.
43. VAN ROSSUM MAJ, FISELIER TJW, FRANSSEN MJAM et al.: Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. (1998) 41:808-816.
44. HUANG JL, CHEN LC: Sulphasalazine in the treatment of children with chronic arthritis. Clin. Rheumatol. (1998) 17:359-363.
45. SAVOLAINEN HA, KAUTIAINEN H, ISOMÄKI H et al.: Azathioprine in patients with juvenile chronic arthritis: a long-term follow-up study. J. Rheumatol. (1997) 24:2444-2450.
46. ANDRASCH RH, PIROFSKY B, BURNS RP: Immunosuppressive therapy for severe chronic uveitis. Arch. Ophthalmol. (1978) 96:247-251.
47. REIFF A, RAWLINGS DJ, SHAHAM B et al.: Preliminary evidence for cyclosporine A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J. Rheumatol. (1997) 24:2436-2443.
48. FANTINI F: Cyclosporine therapy in systemic juvenile rheumatoid arthritis (Still's disease): an open pilot prospective study. In: Cyclosporine in Autoimmune Diseases. Bonomo L (Ed). Il Pensiero Scientifico Editore, Rome, Italy (1990):133-142.
49. GERLONI V, CIMAZ R, GATTINARA M et al.: Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) (2001) 40:907-913.
50. D'AMATO RJ, LOUGHAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082-4085.
51. ZWINGENBERGER K, WENDT S: Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. J. Inflamm. (1996) 46:177-211.
52. CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. (1999) 163:380-386.
53. BESSMERTNY O, Pham T: Thalidomide use in pediatric patients. Ann. Pharmacother. (2002) 36(3):521-525.
54. KARIM MY, RUIZ-IRASTORZA G, KHAMASHTA MA et al.: Update on therapy-thalidomide in the treatment of lupus. Lupus (2001) 10(3):188-192.
55. SCHECHTER SJ, SUNDEL R, OLIVEIRA K et al.: Thalidomide for severe systemic onset JIA. Arthritis Rheum. (2003) 48(Suppl. 9):S122.
56. WALLACE CA, SHERRY DD: Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. (1997) 40:1852-1855.
57. EMERY P, ZEIDLER H, KVIEN TK et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet (1999) 354:2106-2111.
58. SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 282:1921-1928.
59. BENSEN WG, FIECHTNER JJ, MCMILLEN JI et al.: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin. Proc. (1999) 74:1095-105.
60. DAY R, MORRISON B, LUZA A, CASTANEDA O et al.: A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch. Intern. Med. (2000) 160:1781-1787.
61. EHRICH EW, DALLOB A, DE LEPELEIRE I et al.: Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin. Pharmacol. Ther. (1999) 65:336-347.
62. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343(21):1520-1528.
63. KISS MH, REIFF A, REICIN AS et al.: Rofecoxib Demonstrates efficacy and tolerability in children and adolescents (ages 2-17 years) with juvenile rheumatoid arthritis (JRA). In a 12-week randomized study. Arthritis Rheum. (2003) 48(Suppl. 9):S1698.
64. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomized, multicenter trial. Lancet (1999) 353:259-266.
65. MORELAND LW, FLEISCHMANN RM, STRAND V, for the Leflunomide RA Investigators Group: Efficacy of leflunomide versus placebo versus methotrexate in early and late rheumatoid arthritis. Arthritis Rheum. (1998) 41(9 Suppl.):S155.
66. SILVERMAN E, SPIEGEL L, JUNG LK et al.: Efficacy and Safety of Leflunomide (LEF) versus Methotrexate (MTX) in the Treatment of Pediatric Patients with Juvenile Rheumatoid Arthritis (JRA) Arthritis Rheum. (2003) 43: (Suppl. 9) (LB Abstract).
67. EMERY P, BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 39(6):655-665.
68. GOEL A, LONDINO AV JR: FK506 in severe treatment resistant juvenile rheumatoid arthritis (JA). Arthritis Rheum. (1996) 39(Suppl. 9):S192.
69. COHN RG, MIRKOVICH A, DUNLAP B et al.: Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation (1999) 68:411-418.
70. GOLDBLUM R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol. (1993) 11(8 Suppl.):S117-S119.
71. GLICKLICH D, ACHARYA A: Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis. (1998) 32:318-322.
72. BURATTI S, SZER IS, SPENCER H et al.: Mycophenolate mofetil (MMF, Cellcept) in the treatment of severe renal disease in pediatric onset systemic lupus erythematosus (SLE). J. Rheumatol. (2001) 289:2103-2108.
73. GREINER K, VARIKKARA M, SANTIAGO C et al.: Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe (2002) 99(9):691-694.
74. CANNON GW, PINCUS SH, EMKEY RD et al.: Double-blind trial of recombinant γ-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. (1989) 32:964-973.
75. PERNICE W, SCHUCHMANN L, DIPPELL J et al.: Therapy for systemic juvenile rheumatoid arthritis with γ-interferon: a pilot study of nine patients. Arthritis Rheum. (1989) 32:643-646.
76. Immunex Corporation: Enbrel® (etanercept) manufacturer's prescribing information. Immunex Corporation, Seattle, WA, USA (2002).
77. KUTUKCULER N, CAGLAYAN S, AYDOGDU F: Study of pro-inflammatory (TNF-α, IL-1β, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin. Rheumatol. (1998) 17:288-292.
78. GROM AA, MURRAY KJ, LUYRINK L et al.: Patterns of expression of tumor necrosis factor α, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum. (1996) 39:1703-1710.
79. GUERNE PA: Cytokines in juvenile arthritis. Rev. Rhum. Engl. Ed. (1996) 63:153-158.
80. LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N. Engl. J. Med. (2000) 342:763-769.
81. GIANNINI EH, RUPERTO N, RAVELLI A et al.: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. (1997) 40:1202-1209.
82. LOVELL DJ, GIANNINI EH, REIFF A et al.: Long term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. (2003) 48:218-226.
83. REIFF A, TAKEI S, SADEGHI S et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. (2001) 44:1411-1415.
84. REIFF A: Long term outcome of etanercept treatment in children with treatment refractory uveitis (letter). Arthritis Rheum. (2003) 48(7):2079-2080.
85. Centocor, Inc.: Remicade® (infliximab) manufacturer's prescribing information. Centocor, Inc., Malvern, PA, USA (1999).
86. LAHDENNE P, VAHASALO P, HONKANEN V: Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. (2003) 62(3):245-247.
87. GERLONI V, PONTIKAKI I, DESIATI F et al.: Infliximab in the treatment of persistently active refractory juvenile idiopathic (chronic) arthritis: a short-term pilot study. Arthritis Rheum. (2000) 43(9 Suppl.):S1139.
88. BILLIAU AD, CORNILLIE F, WOUTERS C: Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J. Rheum. (2002) 29(5):1111-1114.
89. ELLIOTT MJ, WOO P, CHARLES P et al.: Suppression of fever and the acutephase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor- (cA2). Br. J. Rheumatol. (1997) 36:589-593.
90. ROSENBAUM JT, SMITH JR: Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheum. (2002) 20(6 Suppl. 28):143-145.
91. SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI CG et al.: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet (2001) 358(9278):295-296.
92. EL-SHABRAWI Y, HERMANN J: Anti-TNF α therapy with infliximab in the treatment of HLA B27 associated acute anterior uveitis- a one year follow up. Arthritis Rheum. (2001) 44(Suppl. 9):S123.
93. MOUSER JF, HYAMS JS: Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin. Ther. (1999) 21:932-942.
94. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48(1):35-45; Erratum appears in Arthritis Rheum. (2003) 48(3):855.
95. FURST DH, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of star (safety trial of adalimumab in rheumatoid arthritis. J. Rheum. (2003) 30(12):2563-2571.
96. RAU R, HERBORN G, SANDER O et al.: Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritis Rheum. (1999) 42(9 Suppl.):S400.
97. WOO P, WEDDERBURN LR: Juvenile chronic arthritis. Lancet (1998) 351:969-973.
98. GOTO M, FUJISAWA M, YAMADA A et al.: Spontaneous release of angiotensin converting enzyme and interleukin 1β from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann. Rheum. Dis. (1990) 49:172-176.
99. ZANGERLE PF, DE GROOTE D, LOPEZ M et al.: Direct stimulation of cytokines(IL-1β, TNF-_IL-6, IL-2, IFN-γ and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine (1992) 4:568-575.
100. BRESNIHAN B, ALVARON-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196-204.
101. ILOWITE N, PORRAS O, REIFF A et al.: A twelve-week open label safety and efficacy study of Kineretâ (anakinra) in juvenile rheumatoid arthritis. European League Against Rheumatism Meeting, Lisbon, Portugal (2003) (Abstract).
102. DE BENEDETTI F, MASSA M, PIGNATTI P et al.: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. (1994) 93(5):2114-2119.
103. MAENO N, TAKEI S, NOMURA Y et al.: Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis or in Kawasaki disease. Arthritis Rheum. 46(9):2539-2541.
104. ROONEY M, VARSANI H, MARTIN K et al.: Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis. Rheumatology (2000) 39:432-438.
105. KIMURA Y: Etanercept treatment in refractory systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. (2002) 46(Suppl. 9):S1275.
106. YOKOTA S, MIYAMAE T, IMAGAWA T et al.: Phase II trial of anti IL6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. (2003) 48 (Suppl. 9):S1070.
107. WULFFRAAT NM, KUIS W: Autologous stem cell transplantation: a possible treatment for refractory juvenile chronic arthritis? Rheumatology (1999) 38:64-66.
108. WULFFRAAT NM, VAN ROYEN A, BIERINGS M et al.: Autologous hemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet (1999) 353:550-553.
109. DUREZ P, FERSTER A, TOUNGOUZ M et al.: Autologous T cell depleted CD34+ peripheral blood stem cell transplantation in four patients with refractory rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum. (1999) 42(9 Suppl.):S77.
110. WULFFRAAT NM, BRINKMAN D, FERSTER A et al.: Long term follow up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bonemarrow Transplantation (2003) 32(Suppl. 1):S61-S64.